.
Homeopathy, Momordica charantia 12 CH, BPH, Clinical trial, IL-6,
Immunophenotyping of lymphocytes.
The benign enlargement of the prostate, better known as benign prostatic
hyperplasia (BPH) results in symptoms of the lower urinary tract (LUTS) that
contributes to lower quality of life of men over the fourth decade, and is mostly
treated by allopathic drugs of the group of 5-alpha-reductase inhibitors and / or
alpha-blockers, and / or phytotherapics, as Serenoa repens the most used. The
scientific literature shows lack research from randomised and doubleblind clinical
trials on the efficacy of homeopathic medicinal products that already have
homeopathic medical materia and new homeopathic medicinal for BPH.
The present study aimed to evaluate the effectiveness of the homeopathic product
containing Momordica charantia 12CH in the LUTS control caused by BPH in a
clinical, randomized, double-blind and placebo-controlled trial.A total of 81 patients
were randomized to group A - Placebo and group B - Momordica charantia 12CH
and evaluated at each visit by anamnesis with the International Prostate Symptom
Score (IPSS), by imaging tests measured prostate volume (PV) and post-void
residual (PVR) and laboratory tests for prostate specific antigen (PSA), quantitative
C-reactive protein (CRP) and interleukin-6 (IL-6), and in 72 samples, lymphocyte and
subpopulation immunophenotyping were performed by flow cytometry.Both the main
variable (IPSS) and the secondary variables (PSA, PV, PVR and CRP) and
accessory variables (IL-6, total lymphocytes, B lymphocytes, T lymphocytes, T helper
cells, cytotoxic T lymphocytes and CD4 / CD8 ratio and Natural Killer cells) did not
present statistical significance in the means between the groups treated and
Placebo.About the safety variables, the use of homeopathic medication by the
patients did not interfere during the six months of research, either in the fasting
glucose level, as well as in the dosages of alanine aminotransferase, aspartate
aminotransferase, alkaline phosphatase, total bilirubins and fractions and creatinine
levels used for hepatic evaluation and renal function respectively.The absence of
urinary infection confirmed by urinalysis of patients predominated in both groups A
and B throughout the clinical trial period. Clinical studies with Momordica charantia in other dynamizations to evaluate their effectiveness in the control of LUTS/BPH
should be performed, since in 12CH their action has not been proven